Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rofecoxib: a specific cyclooxygenase inhibitor.

G W Cannon1

  • 1Salt Lake City VA Medical Center and Division of Rheumatology, University of Utah, Salt Lake City, Utah 84148, USA.

Drugs of Today (Barcelona, Spain : 1998)
|July 25, 2003
PubMed
Summary

Rofecoxib, a cyclooxygenase-2 inhibitor, effectively treats osteoarthritis and acute pain with fewer gastrointestinal ulcers than traditional NSAIDs. It offers comparable pain relief with improved safety, similar to placebo regarding ulceration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis<sup>✰</sup>.

Seminars in arthritis and rheumatism·2019
Same author

A comparison of electronic and manual fracture risk assessment tools in screening elderly male US veterans at risk for osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same author

Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.

Arthritis care & research·2014
Same author

Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis.

Clinical and experimental rheumatology·2014
Same author

Poor to modest agreement between rheumatoid arthritis response measures in clinical practice.

Clinical and experimental rheumatology·2009

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Rheumatology

Background:

  • Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor.
  • Established efficacy in osteoarthritis, rheumatoid arthritis, and acute pain management.
  • Approved in the US for osteoarthritis and acute pain.

Purpose of the Study:

  • To evaluate the gastrointestinal safety and efficacy of rofecoxib compared to NSAIDs.
  • To assess rofecoxib's therapeutic benefit and toxicity profile.

Main Methods:

  • Clinical trials comparing rofecoxib to standard NSAIDs and placebo.
  • Endoscopic assessment of gastrointestinal ulceration.

Main Results:

  • Significantly lower rates of endoscopically proven gastrointestinal ulceration with rofecoxib versus NSAIDs.

Related Experiment Videos

  • Ulceration rates with rofecoxib were comparable to placebo.
  • Rofecoxib demonstrated equivalent clinical benefit to standard NSAIDs.

    • Conclusions:

    • Rofecoxib offers a favorable gastrointestinal safety profile compared to traditional NSAIDs.
    • Provides effective pain relief and anti-inflammatory benefits with reduced toxicity.
    • A valuable therapeutic option for conditions requiring NSAID treatment.